Synthesis and Characterization of Two Impurities in Esomeprazole

Synthesis and Characterization of Two Impurities in Esomeprazole

Latin American Journal of Pharmacy
(formerly Acta Farmacéutica Bonaerense)
Lat. Am. J. Pharm. 34 (6): 1265-8 (2015)
Short communication
Received: February 9, 2015
Revised version: April 12, 2015
Accepted: April 14, 2015
Synthesis and Characterization of Two Impurities
in Esomeprazole, an Antiulcerative Drug
Xiao-ping LIU 1,2, Hui-lan XU 1, Rui SUN 2, Xue LI 1, Bao-hua HU 2 & Chun HU 1,2 *
1
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education,
School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
2 Yantai Valiant Fine Chemicals Co. Ltd., Yantai 264006, China.
SUMMARY. Impurity control is a key factor for drug quality. Study for impurities is helpful to optimize
the production process and improve the quality of drugs. Synthesis and characterization of two of impurities in esomeprazole, which used for treatment of acid-related diseases was described in this paper. The
two impurities are known as 2-[(3,5-dimethyl-4-methoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole
(impurity 1) and (R)-5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
(esomeprazole impurity F), whose structures are characterized with MS, IR, 1H-NMR and elemental analyses, and the purities of the two impurities are above 99% by HPLC analysis. The two target compounds
can be used as the reference substance of the impurities of esomeprazole.
RESUMEN. El control de impurezas es un factor clave para la calidad de los medicamentos. El estudio de impurezas es útil para optimizar el proceso de producción y mejorar la calidad de los medicamentos. En este artículo
se comunica la síntesis y caracterización de dos de las impurezas de esomeprazol, utilizado para el tratamiento de
enfermedades relacionadas con la acidez. Las dos impurezas se conocen como 2-[(3,5-dimetil-4-metoxi-2-piridil)
metil sulfinil]-1H-bencimidazol (impureza 1) y (R)-5-metoxi-2-[(4- metoxi-3,5-dimetilpiridin-2-il) metilsulfinil]1H-bencimidazol (impureza esomeprazol F), cuyas estructuras se caracterizan con MS, IR, 1H-RMN y análisis
elemental; la purezas de ambas impurezas está por encima de 99 % mediante análisis por HPLC. Los dos compuestos diana se pueden utilizar como sustancias de referencia de impurezas de esomeprazol.
KEY WORDS: characterization, esomeprazole, impurity, synthesis.
*
Author to whom correspondence should be addressed. E-mail: [email protected]
ISSN 0326 2383 (printed ed.)
ISSN 2362-3853 (on line ed.)
1265